Iovance Biotherapeutics, Inc. (IOVA)
8.12
-0.05
(-0.61%)
USD |
NASDAQ |
Sep 01, 14:44
Iovance Biotherapeutics Cash from Investing (Quarterly) : -74.05M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -74.05M |
| March 31, 2026 | 11.39M |
| December 31, 2025 | 0.775M |
| September 30, 2025 | 17.01M |
| June 30, 2025 | 13.84M |
| March 31, 2025 | 15.87M |
| December 31, 2024 | 23.68M |
| September 30, 2024 | -48.80M |
| June 30, 2024 | 40.22M |
| March 31, 2024 | -111.51M |
| December 31, 2023 | -72.84M |
| September 30, 2023 | -79.01M |
| June 30, 2023 | -156.78M |
| March 31, 2023 | 153.40M |
| December 31, 2022 | 0.461M |
| September 30, 2022 | 73.72M |
| June 30, 2022 | 95.76M |
| March 31, 2022 | 86.52M |
| December 31, 2021 | 69.34M |
| September 30, 2021 | 12.75M |
| June 30, 2021 | -159.16M |
| March 31, 2021 | 77.21M |
| December 31, 2020 | 58.75M |
| September 30, 2020 | -52.96M |
| June 30, 2020 | -423.76M |
| Date | Value |
|---|---|
| March 31, 2020 | 100.10M |
| December 31, 2019 | 26.81M |
| September 30, 2019 | 3.495M |
| June 30, 2019 | 58.68M |
| March 31, 2019 | 1.033M |
| December 31, 2018 | -206.38M |
| September 30, 2018 | -149.37M |
| June 30, 2018 | -30.50M |
| March 31, 2018 | -0.022M |
| December 31, 2017 | 0.058M |
| September 30, 2017 | 14.49M |
| June 30, 2017 | 25.33M |
| March 31, 2017 | 18.80M |
| December 31, 2016 | 25.76M |
| September 30, 2016 | -16.56M |
| June 30, 2016 | -0.167M |
| March 31, 2016 | -0.147M |
| December 31, 2015 | 9.737M |
| September 30, 2015 | -0.2127M |
| June 30, 2015 | -99.90M |
| March 31, 2015 | -0.7821M |
| December 31, 2014 | -1.426M |
| September 30, 2014 | -0.1603M |
| June 30, 2014 | -0.0023M |
| March 31, 2014 | -0.0034M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Amgen, Inc. | -569.00M |
| Halozyme Therapeutics, Inc. | -62.66M |
| Neurocrine Biosciences, Inc. | -135.40M |
| AVITA Medical, Inc. | 3.947M |
| Editas Medicine, Inc. | -29.80M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -60.84M |
| Cash from Financing (Quarterly) | 49.29M |
| Free Cash Flow | -296.40M |
| Free Cash Flow Per Share (Quarterly) | -0.1472 |
| Free Cash Flow to Equity (Quarterly) | -64.51M |
| Free Cash Flow to Firm (Quarterly) | -66.28M |
| Free Cash Flow Yield | -8.90% |